John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 283,154 shares at $310.02 ($89.4M) on 2026-07-15, disclosed to the SEC on 2026-07-17.
Scheduled sale ($89.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $310.02 | 6,067 | $1.9M | 2.1% |
| 2 | $310.92 | 41,336 | $12.9M | 14.4% |
| 3 | $311.71 | 12,857 | $4.0M | 4.5% |
| 4 | $312.86 | 48,657 | $15.2M | 17.0% |
| 5 | $313.58 | 7,640 | $2.4M | 2.7% |
| 6 | $311.98 | 233 |
| $73K |
| 0.1% |
| 7 | $314.08 | 4,881 | $1.5M | 1.7% |
| 8 | $314.73 | 9,516 | $3.0M | 3.4% |
| 9 | $316.00 | 19,752 | $6.2M | 7.0% |
| 10 | $316.82 | 32,224 | $10.2M | 11.4% |
| 11 | $317.79 | 42,798 | $13.6M | 15.2% |
| 12 | $318.55 | 6,402 | $2.0M | 2.3% |
| 13 | $319.99 | 15,097 | $4.8M | 5.4% |
| 14 | $321.00 | 20,505 | $6.6M | 7.4% |
| 15 | $321.61 | 13,109 | $4.2M | 4.7% |
| 16 | $322.71 | 1,560 | $503K | 0.6% |
| 17 | $323.59 | 520 | $168K | 0.2% |
| Total | $315.56 avg | 283,154 | $89.4M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $18.3M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |